Integer Holdings Corporation (ITGR)

Over the past six months, Integer Holdings Corp. stock has experienced several notable events and price movements. On October 23, 2025, Integer reported its Q3 2025 earnings, with the Cardio & Vascular segment showing double-digit growth, but the stock plunged amid disappointing results and a CEO transition announcement. In October 2025, Payman Khales assumed the role of President and CEO. On February 19, 2026, Integer reported its Q4 and full-year 2025 results, announcing revenue growth, but the stock declined, possibly due to investor disappointment with guidance. On April 6, 2026, Integer announced a Board Leadership Transition. On April 30, 2026, Integer announced its Q1 2026 results, with sales increasing, but GAAP and adjusted operating income decreased. On April 30, 2026, the Board of Directors initiated a strategic review to explore various options, including a potential sale, merger, or strategic business combination. The stock's 52-week low was $62.00 on October 30, 2025, and its 52-week high was $127.56 on April 29, 2025. As of April 28, 2026, the share price was $84.63.

Based on the available information, there is no explicit mention of clear seasonal demand patterns for Integer Holdings Corp.'s products and services. However, revenue growth sustainability has been flagged as being at risk from demand timing and product attrition. Warnings about timing shifts and customer concentration suggest that demand can be influenced by specific customer behaviors and market conditions. The company has experienced challenges in certain product lines, leading to revised guidance and a lowered outlook. While management remains optimistic about the overall market demand for their products, these specific disruptions have caused concern.

Integer Holdings Corp. is a global medical device contract development and manufacturing organization (CDMO) that partners with medical device companies and original equipment manufacturers (OEMs) worldwide. The company operates within the healthcare sector, specifically in the medical devices industry, and is classified under surgical and medical instrument manufacturing. Its core business involves designing, developing, and manufacturing medical devices and components. Its major product lines are Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets.

Integer Holdings Corp. has a global geographic footprint, with its corporate headquarters located in Plano, Texas, USA. The company generates a significant portion of its revenue in the United States. Beyond the U.S., Integer maintains a presence in Ireland, Puerto Rico, Costa Rica, the Dominican Republic, Malaysia, Mexico, Switzerland, and Uruguay, encompassing administrative, manufacturing, and research and development (R&D) locations.

Integer Holdings Corporation generally maintains a positive sentiment within the industry and sector. The company is recognized as an industry leader with world-class engineering and manufacturing capabilities, strong customer relationships, and a robust product portfolio. However, disappointing Q3 2025 earnings and a CEO transition, revised 2026 guidance, Q1 2026 performance and a strategic review, and product headwinds have likely impacted investor confidence and aspects of its reputation.

Integer Holdings Corporation's ownership is primarily distributed among institutional investors, holding approximately 98.55% to 108.90% of the stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Dimensional Fund Advisors Lp, State Street Corp, Invesco Ltd., Irenic Capital Management LP, Alliancebernstein L.p., Earnest Partners Llc, Geode Capital Management, Llc, and Morgan Stanley. Blackrock Inc. is noted as the largest individual Integer Holdings shareholder. Retail investors hold a smaller percentage, with figures ranging from 0.00% to 27.82%. Insiders hold approximately 1.04% to 4.76% of the company's stock, and insider activity in the past three months has shown a slight sell-off.